Premium
Beta‐blocker therapy is not associated with mortality after intracerebral hemorrhage
Author(s) -
Sykora M.,
Putaala J.,
Meretoja A.,
Tatlisumak T.,
Strbian D.
Publication year - 2018
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12817
Subject(s) - medicine , atrial fibrillation , antithrombotic , intracerebral hemorrhage , stroke (engine) , diabetes mellitus , heart failure , retrospective cohort study , cardiology , subarachnoid hemorrhage , mechanical engineering , engineering , endocrinology
Background Beta‐blocker therapy has been suggested to have neuroprotective properties in the setting of acute stroke; however, the evidence is weak and contradictory. We aimed to examine the effects of pre‐admission therapy with beta‐blockers ( BB ) on the mortality following spontaneous intracerebral hemorrhage ( ICH ). Methods Retrospective analysis of the Helsinki ICH Study database. Results A total of 1013 patients with ICH were included in the analysis. Patients taking BB were significantly older, had a higher premorbid mRS score, had more DNR orders, and more comorbidities as atrial fibrillation, hypertension, diabetes mellitus, ischemic heart disease, and heart failure. After adjustment for age, pre‐existing comorbidities, and prior use of antithrombotic and antihypertensive medications, no differences in in‐hospital mortality ( OR 1.1, 95% CI 0.8‐1.7), 12‐month mortality ( OR 1.3, 95% CI 0.9‐1.9), and 3‐month mortality ( OR 1.2, 95% CI 0.8‐1.7) emerged. Conclusion Pre‐admission use of BB was not associated with mortality after ICH .